Cargando…

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines

Antigen-specific immunotherapy using DNA vaccines has emerged as an attractive approach for the control of tumors. Another novel cancer therapy involves the employment of the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). In the current study, we aimed to test the combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Shiwen, Monie, Archana, Pang, Xiaowu, Hung, Chien-Fu, Wu, T-C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062584/ https://www.ncbi.nlm.nih.gov/pubmed/21385449 http://dx.doi.org/10.1186/1423-0127-18-21

Ejemplares similares

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
por: Chuang, Chi-Mu, et al.
Publicado: (2009)

Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
por: Chuang, Chi-Mu, et al.
Publicado: (2010)

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination
por: Yang, Benjamin, et al.
Publicado: (2015)

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
por: Wu, Chao-Yi, et al.
Publicado: (2010)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
por: Mao, Chih-Ping, et al.
Publicado: (2011)

Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus
por: Yang, Andrew, et al.
Publicado: (2017)

Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation
por: Sun, Yunyan, et al.
Publicado: (2017)

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
por: Drzyzga, Alina, et al.
Publicado: (2021)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2018)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions
por: Peng, Shiwen, et al.
Publicado: (2010)

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
por: Roberts, Zachary J., et al.
Publicado: (2007)

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
por: Tang, Choon Kit, et al.
Publicado: (2013)

Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines
por: Lee, Sung Yong, et al.
Publicado: (2019)

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
por: Tseng, Chih-Wen, et al.
Publicado: (2008)

Depletion of platelets enhances therapeutic antitumor effects generated by therapeutic DNA vaccine
por: Lee, Sung Yong, et al.
Publicado: (2013)

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
por: Peng, Shiwen, et al.
Publicado: (2014)

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine
por: Tseng, Ssu-Hsueh, et al.
Publicado: (2021)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
por: Rickardson, Linda, et al.
Publicado: (2017)

Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors
por: Kim, Daejin, et al.
Publicado: (2010)

Perspectives for therapeutic HPV vaccine development
por: Yang, Andrew, et al.
Publicado: (2016)

Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8(+) T cell immune response and antitumor effects in a preclinical cervical cancer model
por: Huang, Zhuomin, et al.
Publicado: (2015)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice
por: Peng, Shiwen, et al.
Publicado: (2022)

Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems
por: Tahamtan, Alireza, et al.
Publicado: (2014)

Cryoablation therapy stimulates the antigen-specific T cell immune responses generated by therapeutic HPV DNA vaccine
por: Lee, Sung Yong, et al.
Publicado: (2015)

Innovative DNA Vaccine for Human Papillomavirus (HPV)-Associated Head and Neck Cancer
por: Wu, Annie, et al.
Publicado: (2010)

Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
por: Gao, Pu, et al.
Publicado: (2014)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA
por: Kang, Tae Heung, et al.
Publicado: (2009)

Salmonella as an Innovative Therapeutic Antitumor Agent
por: Chang, Wen-Wei, et al.
Publicado: (2014)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_fjechgujvboc6c3l730polnfh7